Ignite Creation Date:
2024-06-16 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06426823
Status:
RECRUITING
Last Update Posted:
2024-05-23
First Post:
2024-05-06
Brief Title:
The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes
Sponsor:
University of Copenhagen
Organization:
University of Copenhagen
Study Overview
Official Title:
The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GA-17b
Brief Summary:
This project will describe the mechanisms of action and the relative contributions of GIP to changes in gastrointestinal blood flow induced by oral glucose and endogenous GIP with the use of a receptor antagonists GIP3-30NH2 in patients with type 2 diabetes
Detailed Description:
Each participant will attend four independent randomised experimental days in the MRI-scanner with intravenous infusion hormoneplacebo and oral ingestion glucosewater An intravenous infusion of saline or GIP3-30NH2 starts at time point -20 minutesThe infusions are combined with an oral glucose tolerance test 75 gram of glucose dissolved in 250 ml water ingested orally at time point 0 minutes on two of the experimental days with and without GIP3-30NH2
MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines pancreas and bones
MRI measurements are repeatedly performed and blood samples are drawn to be analysed for endocrine responses from the intestines pancreas and bones
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None